Treats Stage III colon cancer as a single agent. ANDA 91649, held by Teva Pharms USA. Capecitabine.
As of Nov 16, 2026, ANDA 91649 (Capecitabine), held by Teva Pharms USA, was first approved by FDA on Sep 16, 2013, with 9 approved supplements and 0 published complete response letters.
Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2013 | Original application | Approved |
| Capecitabine150MG · tablet;oral | Capecitabine | Rx |
| Capecitabine500MG · tablet;oral | Capecitabine | Rx |
| Jul 10, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 27, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 18, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 18, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 27, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 5, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 24, 2014 | Supplement 1Manufacturing | Approved | None posted |
| Sep 16, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters